九州通2024年业绩稳中有进，一季度净利大增80.38%

Core Insights - The company reported stable growth in its 2024 annual report and Q1 2025 results, with 2024 revenue reaching 151.81 billion yuan and net profit attributable to shareholders at 2.507 billion yuan, reflecting a year-on-year increase of 39.88% [1][4] - The company is focusing on high-quality development and strategic transformation, emphasizing new products, new retail, new medical services, digitalization, and real estate securitization [1][6] Financial Performance - In 2024, the company achieved a revenue of 151.81 billion yuan, with a net profit of 2.507 billion yuan, and a non-recurring net profit of 1.814 billion yuan, showing a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% [1][4] - For Q1 2025, the company reported a revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, marking an 80.38% increase compared to the same period last year [1] Strategic Initiatives - The company is implementing a comprehensive service model that integrates pharmaceutical distribution, logistics, and product promotion, transitioning from traditional distribution to digital and platform-based services [4] - The company has established a full industry chain layout for traditional Chinese medicine, achieving a sales revenue of 4.962 billion yuan, with a year-on-year growth of 18.14% [5] - The company is actively developing digital logistics and supply chain solutions, with this segment generating 1.064 billion yuan in revenue, a 25.32% increase year-on-year [5] Social Responsibility and Shareholder Returns - In 2024, the company donated nearly 18.21 million yuan for public welfare, focusing on energy conservation, rural revitalization, and disaster relief [2][11] - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares, totaling 999.7 million yuan, which, along with a stock buyback of 268 million yuan, amounts to 1.265 billion yuan, representing 50.47% of the annual net profit [2][12] Talent Acquisition and Future Outlook - The company has introduced 264 high-end professionals to support its strategic transformation, with a significant increase in investment for talent acquisition [12][13] - Looking ahead, 2025 is seen as a crucial year for the company to finalize its three-year strategic plan and continue advancing its transformation initiatives [13]